Videos / Recombinant respiratory syncytial virus pre-fusion F protein vaccine

Product Explainer

Recombinant respiratory syncytial virus pre-fusion F protein vaccine

Description

In this Product Explainer, Infectious Disease Physician and Microbiologist Prof Paul Griffin explains the role of a recombinant respiratory syncytial virus pre-fusion F protein vaccine for prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).

Additional resources

NCIRS FAQ: Respiratory syncytial virus (RSV) FAQs | NCIRS.
NCIRS Fact Sheet – state funding of Nirsevimab, eligibility criteria by state: State and territory nirsevimab program summary 2025.pdf

NEXT LIVE Webcast

Days

Hours

Minutes

Seconds

A/Prof Daryl Efron

Autism & Mental Health Comorbidities

Expert panel – Dr Georgia Rigas & Dr Nadia Tejani, facilitated by Dr Angela Kwong

Navigating Perimenopause and Menopause – Managing Weight, Health and Wellbeing in General Practice

Dr Rebecca Purvis

Pharmacogenomics in General Practice

Scientia Prof Kaarin Anstey

New Brain Health Guidelines – What GPs Can Do

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

04 August 2026

expert

Prof Paul Griffin

Infectious Diseases Physician and Clinical Microbiologist; Director of Infectious Diseases, Mater Hospital; Lecturer, University of Queensland

Product Explainer

Recombinant respiratory syncytial virus pre-fusion F protein vaccine